Clinical Trial Update: Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating denosumab as a model for rank-mediated immunologic modulation in virus-related nasopharyngeal carcinoma (EBV-related).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebv-related Carcinoma
• Nasopharyngeal Carcinoma

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Nasopharyngeal Carcinoma, EBV Related Carcinoma | Phase 2 | Status: UNKNOWN